Decrease in Dipeptidyl Peptidase IV Activity is Linked to the Efficacy of Differentiating Compounds in Follicular Thyroid Carcinoma Cell Lines

E. Fröhlich; E. Engel; R. Wahl

doi:10.1055/s-0031-1273682

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2011; 43(5): 364-366
DOI: 10.1055/s-0031-1273682

Short Communication

Decrease in Dipeptidyl Peptidase IV Activity is Linked to the Efficacy of Differentiating Compounds in Follicular Thyroid Carcinoma Cell Lines

E. Fröhlich¹ ^, ² , E. Engel³ , R. Wahl¹

¹Internal Medicine, Department IV, University of Tübingen, Tübingen, Germany
²Center for Medical Research, Medical University of Graz, Graz, Austria
³Institute of Anatomy, University of Tübingen, Germany

Abstract

Metastasized differentiated thyroid carcinoma is treated by surgery followed by radioiodine remnant ablation. The application of differentiating agents is a possibility of increasing the efficacy of radioiodine therapy. We evaluated DPP IV and aminopeptidase N, both linked to malignancy in thyroid carcinoma, and dipeptidyl peptidase II activities in human follicular thyroid carcinoma cell lines upon treatment with retinol, apicidine, and lovastatin as differentiating agents. Decrease of dipeptidyl peptidase IV (DPP IV) activity may play a role in the differentiating action. In the human cancer cell lines FTC 138 and 238, high DPP IV and low aminopeptidase N activities were recorded. Retinol treatment induced increases in thyroid-specific protein expression [thyroglobulin and sodium-iodide symporter (NIS)], increase in iodide uptake, and decrease in thymidine uptake accompanied by decrease in DPP IV activity. Decreases in DPP IV activities were also seen upon apicidine and lovastatin treatment, which also increased differentiation of the transformed thyrocytes. Our results demonstrate a link between decrease in DPP IV activity and increase in iodide uptake upon stimulation with differentiating agents.

Full Text

References

1 Coelho S, Vaisman M, Carvalho D. Curr Pharm Des. 2005; 11 2525-2531
2 Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C. Cancer Res. 2003; 63 8500-8506
3 Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE. Thyroid. 2006; 16 161-175
4 Aratake Y, Kotani T, Tamura K, Araki Y, Kuribayashi T, Konoe K, Ohtaki S. Am J Clin Pathol. 1991; 96 306-310
5 Maes MB, Scharpe S, De Meester I. Clin Chim Acta. 2007; 380 31-49
6 Fröhlich E, Maier E, Mack A, Garbe C. J Dermatol Sci. 2009; 53 68-71
7 Wahl R, Brossart P, Eizenberger D, Schuch H, Kallee E. J Endocrinol Invest. 1992; 15 345-351
8 Fröhlich E, Czarnocka B, Brossart P, Wahl R. Thyroid. 2008; 18 1183-1193
9 Wilson MJ, Ruhland AR, Quast BJ, Reddy PK, Ewing SL, Sinha AA. J Androl. 2000; 21 220-226
10 Freemantle SJ, Spinella MJ, Dmitrovsky E. Oncogene. 2003; 22 7305-7315

Correspondence

R. Wahl

Internal Medicine

Department of Endocrinolgy,

Metabolism, Nephrology and

Clinical Chemistry

University of Tübingen

Otfried-Müller-Straße 10

72076 Tübingen

Germany

Phone: +49/7071/29 83136

Fax: +49/7071/29 3136

Email: richard.wahl@med.uni-tuebingen.de